Compare · EOLS vs NVO
EOLS vs NVO
Side-by-side comparison of Evolus Inc. (EOLS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EOLS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 416.3x EOLS ($439.9M).
- Over the past year, EOLS is down 30.8% and NVO is down 45.7% - EOLS leads by 14.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for EOLS).
- NVO has more recent analyst coverage (25 ratings vs 7 for EOLS).
- Company
- Evolus Inc.
- Novo Nordisk A/S
- Price
- $6.68+0.00%
- $41.01-4.51%
- Market cap
- $439.9M
- $183.15B
- 1M return
- +4.37%
- -10.44%
- 1Y return
- -30.85%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 8
- Recent ratings
- 7
- 25
Evolus Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EOLS
- SEC Form S-3 filed by Evolus Inc.
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
- Evolus to Participate in The Jefferies Global Healthcare Conference
- Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
- SEC Form 10-Q filed by Evolus Inc.
- Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
- SEC Form DEF 14A filed by Evolus Inc.
- SEC Form DEFA14A filed by Evolus Inc.
- Evolus to Report First Quarter Financial Results on May 4, 2026
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care